Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Technique Rapidly Detects Needle-in-a-Haystack Plasma Biomarkers for Disease Diagnosis

By LabMedica International staff writers
Posted on 12 May 2023

Blood plasma, routinely collected during medical care and research, has the potential to be an abundant source of protein biomarkers. More...

These markers can serve diagnostic and prognostic roles, measure treatment response, and provide insights into disease biology. However, finding such biomarkers in plasma using proteomics, the most advanced tool currently available, is challenging. This is because 99% of plasma is composed of common proteins like albumin, globulins, and coagulants that essentially hide potential biomarkers. These same proteins are repeatedly identified in a plasma sample, making the detection of the less abundant but interesting proteins difficult. While scientists have attempted to remove these common proteins from plasma samples using antibodies, the process has been found to be costly, time-consuming, and not robust enough for large-scale usage. Now, a team of researchers has developed a new, rapid, and cost-effective method to remove these proteins by repurposing an old biochemical technique from 1948.

Researchers at Boston Children's Hospital (Boston, MA, USA) came upon a technique previously mentioned in literature on protein and peptide studies that could be applied to plasma. During the COVID-19 pandemic, the researchers were tasked with analyzing the proteins in 5,000 plasma samples for a study looking at immune responses in about 1,100 hospitalized COVID-19 patients. This task had to be accomplished at a time when many labs were closed due to the pandemic. In a span of three months, the researchers had to develop a method to analyze ten times the amount of plasma samples than they typically handled daily. The team successfully accomplished this task, and their work contributed to the identification of tissue- and organ-specific biomarkers, which accurately predicted the progression of hospitalized COVID-19 patients.

This new technique employs perchloric acid, a very potent superacid, along with very low temperatures (-20°C) to separate the common proteins within as little as 15 minutes, without harming the remaining proteins. The unwanted proteins coagulate similar to how milk curdles in lemon juice. The samples can then be centrifuged, and the liquid at the top, which contains the required proteins, can be collected. This method is fast enough for large-scale use, depleting the unwanted proteins at a cost of only USD 2.50 per sample, significantly lower than current costs. This technique enables the detection of over 1,500 proteins per sample at a rate of 60 samples per day.

Related Links:
Boston Children's Hospital 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.